Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
September 20, 2004
- MONITOR
September 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 20, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 13, 2004
- REGULATORY NEWS IN BRIEF
September 13, 2004
- Semi-annual Business Results
September 13, 2004
- Importance of New Safety Measures Stressed: Mr Asonuma of PFSB
September 13, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 13, 2004
- Precautions against Interstitial Pneumonia Required for 220 Active Ingredients: PFSB
September 13, 2004
- OTC NEWS IN BRIEF
September 13, 2004
- Korosho to Further Promote Mutual GMP Recognition of Drugs
September 13, 2004
- PRESS SEMINAR
September 13, 2004
- Specialized Pharmacists Needed in Specific Fields: Mr Ishii
September 13, 2004
- Results of PII Trial of CS-747 Announced at ESC 2004: Sankyo
September 13, 2004
- Monkasho to Request 13% Increase in FY2005 Budget
September 13, 2004
- CHARM Study Reconfirms Efficacy of Candesartan in CHF: Takeda
September 13, 2004
- HPB Seeks 41.3% Increase in Spending on Medical Safety Measures in FY2005
September 13, 2004
- NEW PRODUCTS
September 13, 2004
- Japanese Gov't Should Strengthen Infrastructure of the Pharm Industry: Mr Taurel of Eli Lilly
September 13, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…